|
25/04/2024
|
15:46
|
Change of Name
|
RNS
|
|
22/04/2024
|
10:11
|
Holding(s) in Company
|
RNS
|
|
11/04/2024
|
15:04
|
Holding(s) in Company
|
RNS
|
|
09/04/2024
|
07:00
|
Holding(s) in Company
|
RNS
|
|
08/04/2024
|
16:03
|
Holding(s) in Company
|
RNS
|
|
05/04/2024
|
15:39
|
Director/PDMR Shareholding
|
RNS
|
|
05/04/2024
|
14:40
|
Holding(s) in Company
|
RNS
|
|
04/04/2024
|
13:59
|
Result of General Meeting
|
RNS
|
|
04/04/2024
|
07:00
|
Result of Retail Offer
|
RNS
|
|
19/03/2024
|
17:03
|
Retail Offer
|
RNS
|
|
19/03/2024
|
17:00
|
Acquisition, Fundraising and Change of Name
|
RNS
|
|
09/02/2024
|
11:01
|
Notice of Dispute lodged with Stalicla SA
|
RNS
|
|
29/12/2023
|
11:29
|
Holding(s) in Company
|
RNS
|
|
22/12/2023
|
07:00
|
Directorate Changes
|
RNS
|
|
31/10/2023
|
07:00
|
Half-year Report
|
RNS
|
|
05/09/2023
|
07:00
|
Directorate Changes
|
RNS
|
|
15/08/2023
|
07:00
|
Final Report from Phase 1b PK/PD study
|
RNS
|
|
03/08/2023
|
12:38
|
Rule 17 Disclosure
|
RNS
|
|
02/08/2023
|
07:00
|
Return of rights to Sulforadex from Juvenescence
|
RNS
|
|
21/07/2023
|
12:02
|
Result of AGM
|
RNS
|
|
20/06/2023
|
13:59
|
Notice of AGM & Posting of Annual Report
|
RNS
|
|
19/06/2023
|
07:00
|
Grant Success for Glioblastoma studies
|
RNS
|
|
07/06/2023
|
07:00
|
Final Results
|
RNS
|
|
26/05/2023
|
11:00
|
Notice of Results
|
RNS
|
|
22/03/2023
|
07:00
|
Preliminary results from Phase 1b study
|
RNS
|
|
16/03/2023
|
14:00
|
Price Monitoring Extension
|
RNS
|
|
16/03/2023
|
11:05
|
Second Price Monitoring Extn
|
RNS
|
|
16/03/2023
|
11:00
|
Price Monitoring Extension
|
RNS
|
|
13/03/2023
|
07:00
|
No exposure to Silicon Valley Bank
|
RNS
|
|
25/01/2023
|
07:00
|
Clinical trial update
|
RNS
|
|
14/12/2022
|
17:08
|
Grant of Options - Director/PDMR Shareholding
|
RNS
|
|
12/12/2022
|
11:54
|
Evgen Pharma 'cash runway in pretty good shape'
|
EQS Group
|
|
08/12/2022
|
07:00
|
Half-year Report
|
RNS
|
|
02/12/2022
|
07:00
|
Notice of Half Year Results
|
RNS
|
|
30/11/2022
|
14:06
|
Second Price Monitoring Extn
|
RNS
|
|
30/11/2022
|
14:00
|
Price Monitoring Extension
|
RNS
|
|
16/11/2022
|
07:00
|
Study started of new SFX-01 tablet formulation
|
RNS
|
|
21/10/2022
|
11:05
|
Second Price Monitoring Extn
|
RNS
|
|
21/10/2022
|
11:00
|
Price Monitoring Extension
|
RNS
|
|
12/10/2022
|
16:41
|
Second Price Monitoring Extn
|
RNS
|
|
12/10/2022
|
16:35
|
Price Monitoring Extension
|
RNS
|
|
12/10/2022
|
07:00
|
Clinical trial update
|
RNS
|
|
10/10/2022
|
11:05
|
Second Price Monitoring Extn
|
RNS
|
|
10/10/2022
|
11:00
|
Price Monitoring Extension
|
RNS
|
|
10/10/2022
|
07:00
|
SFX-01 licensing deal for up to $160.5m
|
RNS
|
|
29/09/2022
|
07:00
|
Regulatory approval for healthy volunteer study
|
RNS
|
|
22/07/2022
|
07:00
|
Result of AGM
|
RNS
|
|
14/07/2022
|
12:43
|
Investor Presentation
|
RNS
|
|
06/07/2022
|
12:25
|
Notice of AGM
|
RNS
|
|
13/06/2022
|
07:00
|
Collaboration with University of Michigan
|
RNS
|